» Articles » PMID: 24429216

Human Fetal Membranes Generate Distinct Cytokine Profiles in Response to Bacterial Toll-like Receptor and Nod-like Receptor Agonists

Overview
Journal Biol Reprod
Date 2014 Jan 17
PMID 24429216
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Bacterial infection-associated inflammation is thought to be a major cause of preterm premature rupture of membranes. Proinflammatory cytokines, such as interleukin 1B (IL1B), can weaken fetal membranes (FM) by upregulating matrix metalloproteinases and inducing apoptosis. The mechanism by which infection leads to inflammation at the maternal-fetal interface and subsequent preterm birth is thought to involve innate immune pattern recognition receptors (PRR), such as the Toll-like receptors (TLR) and Nod-like receptors (NLR), which recognize pathogen-associated molecular patterns (PAMPs). The objective of this study was to determine the cytokine profile generated by FMs in response to the bacterial TLR and NLR agonists peptidoglycan (PDG; TLR2), lipopolysaccharide (LPS; TLR4), flagellin (TLR5), CpG ODN (TLR9), iE-DAP (Nod1), and MDP (Nod2). PDG, LPS, flagellin, iE-DAP, and MDP triggered FMs to generate an inflammatory response, but the cytokine profiles were distinct for each TLR and NLR agonist, and only IL1B and RANTES were commonly upregulated in response to all five PAMPs. CpG ODN, in contrast, had a mild stimulatory effect only on MCP-1 and primarily downregulated basal FM cytokine production. IL1B secretion induced by PDG, LPS, flagellin, iE-DAP, and MDP was associated with its processing. Furthermore, FM IL1B secretion in response to TLR2, TLR4, and TLR5 activation was caspase 1-dependent, whereas Nod1 and Nod2 induced IL1B secretion independent of caspase 1. These findings demonstrate that FMs respond to different bacterial TLR and NLR PAMPs by generating distinct inflammatory cytokine profiles through distinct mechanisms that are specific to the innate immune PRR activated.

Citing Articles

Buprenorphine induces human fetal membrane sterile inflammation.

Lynn T, Kelleher M, Georges H, McCauley E, Logan R, Yonkers K J Reprod Immunol. 2025; 168:104445.

PMID: 39914058 PMC: 11890952. DOI: 10.1016/j.jri.2025.104445.


Contractile responses of engineered human myometrium to prostaglandins and inflammatory cytokines.

Maxey A, Wheeler S, Travis J, McCain M APL Bioeng. 2024; 8(4):046115.

PMID: 39734362 PMC: 11672207. DOI: 10.1063/5.0233737.


TLR8-activating miR-146a-3p is an intermediate signal contributing to fetal membrane inflammation in response to bacterial LPS.

Georges H, Cassin C, Tong M, Abrahams V Immunology. 2024; 172(4):577-587.

PMID: 38631842 PMC: 11223956. DOI: 10.1111/imm.13794.


Maternal Infection and Preterm Birth: From Molecular Basis to Clinical Implications.

Daskalakis G, Psarris A, Koutras A, Fasoulakis Z, Prokopakis I, Varthaliti A Children (Basel). 2023; 10(5).

PMID: 37238455 PMC: 10217143. DOI: 10.3390/children10050907.


Intrinsic sexual dimorphism in the placenta determines the differential response to benzene exposure.

Maxwell A, Adzibolosu N, Hu A, You Y, Stemmer P, Ruden D iScience. 2023; 26(4):106287.

PMID: 37153445 PMC: 10156617. DOI: 10.1016/j.isci.2023.106287.


References
1.
Romero R, Mazor M, Brandt F, Sepulveda W, Avila C, Cotton D . Interleukin-1 alpha and interleukin-1 beta in preterm and term human parturition. Am J Reprod Immunol. 1992; 27(3-4):117-23. DOI: 10.1111/j.1600-0897.1992.tb00737.x. View

2.
Girardin S, Boneca I, Carneiro L, Antignac A, Jehanno M, Viala J . Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science. 2003; 300(5625):1584-7. DOI: 10.1126/science.1084677. View

3.
Abrahams V . Pattern recognition at the maternal-fetal interface. Immunol Invest. 2008; 37(5):427-47. DOI: 10.1080/08820130802191599. View

4.
Caughey A, Robinson J, Norwitz E . Contemporary diagnosis and management of preterm premature rupture of membranes. Rev Obstet Gynecol. 2008; 1(1):11-22. PMC: 2492588. View

5.
Akira S, Takeda K . Toll-like receptor signalling. Nat Rev Immunol. 2004; 4(7):499-511. DOI: 10.1038/nri1391. View